公开(公告)号：KR1020130105545A

公开(公告)日：2013-09-25

申请号：KR1020130028183

申请日：2013-03-15

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  박미경 ,  이선영 ,  허양미 ,  박진실 ,  문영미 ,  임미애 ,  정정희

IPC: C12N15/63 ,  C12N15/85 ,  A61K35/12

Abstract: PURPOSE: An ROR alpha is provided to suppress the activation of Th17 cells and to regulate immune response, thereby effectively treating and preventing various allergic diseases or autoimmune diseases. CONSTITUTION: A method for reducing the activation of Th17 cells comprises the step of promoting the expression or activation of ROR alpha by transducing a recombinant expression vector containing ROR alpha genes into Th17 cells. ROR alpha gene has a sequence of sequence number 11 or 12. The recombinant expression vector contains a promoter or an enhancer which promotes the expression or activation of ROR alpha. A composition for preventing and treating Th17 cell activation-related diseases contains an agent for promoting the expression or activation of ROR alpha; or Th17 cells in which the agent is transduced, as an active ingredient.

Abstract translation: 目的：提供RORα以抑制Th17细胞的活化并调节免疫应答，从而有效治疗和预防各种过敏性疾病或自身免疫性疾病。 构成：减少Th17细胞活化的方法包括通过将含有RORα基因的重组表达载体转导入Th17细胞来促进RORα的表达或活化的步骤。 RORα基因具有序列号11或12的序列。重组表达载体含有促进RORα表达或活化的启动子或增强子。 用于预防和治疗Th17细胞活化相关疾病的组合物含有促进RORα的表达或活化的药剂; 或Th17细胞作为活性成分。

公开(公告)号：KR1020130090055A

公开(公告)日：2013-08-13

申请号：KR1020120011093

申请日：2012-02-03

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  문영미 ,  이선영

IPC: C07K19/00 ,  C12N15/62 ,  A61K38/17 ,  A61P37/00

CPC classification number: C07K14/4703 ,  A61K38/1709 ,  A61K47/64 ,  C07K7/08 ,  C07K2319/03

Abstract: PURPOSE: R12-PIAS3 fusion peptide is provided to be usefully used as an immune suppressant or a pharmaceutical composition which prevents or treats immune disease including autoimmune disease due to the dysregulation of an immune reaction, inflammation disease and transplantation rejection disease. CONSTITUTION: Recombinant peptide in which twelve successive arginene (R) and PIAS3 are fused is provided. The recombinant peptide has an amino acid sequence represented by a sequence number 1. A vector includes a base sequence coding the peptide. The base sequence comprises a base sequence represented by a sequence number 2. A composition for prevention or treatment of immune disease includes the peptide.

Abstract translation: 目的：提供R12-PIAS3融合肽有效地用作免疫抑制剂或药物组合物，其可防止或治疗由于免疫反应失调引起的自身免疫疾病，炎症疾病和移植排斥疾病的免疫疾病。 构成：提供其中十二个连续的精氨酸（R）和PIAS3融合的重组肽。 重组肽具有由序列号1表示的氨基酸序列。载体包括编码该肽的碱基序列。 碱基序列包含由序列号2表示的碱基序列。用于预防或治疗免疫疾病的组合物包括该肽。

公开(公告)号：KR1020130032465A

公开(公告)日：2013-04-02

申请号：KR1020110096057

申请日：2011-09-23

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  조석구 ,  박민정 ,  임정연 ,  임건일 ,  이성희 ,  이은정

IPC: A61K48/00 ,  A61K35/28

CPC classification number: A61K48/00 ,  A61K35/28 ,  A61K48/005 ,  A61K48/0075

Abstract: PURPOSE: A cell therapeutic composition is provided to effectively suppress immune rejection from a transplant process, and to prevent or treat graft-versus-host disease. CONSTITUTION: A pharmaceutical composition for preventing or treating graft-versus-host disease contains 1ug/ul-3ug/ul of genes which suppresses an IL-21 receptor and 2x10^5-2x10^7 mesenchymal stem cells as an active ingredient. The mesenchymal stem cells are derived from human.

Abstract translation: 目的：提供细胞治疗组合物以有效抑制移植过程的免疫排斥，并预防或治疗移植物抗宿主病。 构成：用于预防或治疗移植物抗宿主病的药物组合物含有1ug / ul-3ug / ul的基因，其抑制IL-21受体和2×10 ^ 5-2×10 ^ 7间充质干细胞作为活性成分。 间充质干细胞来源于人。

公开(公告)号：KR1020120118978A

公开(公告)日：2012-10-30

申请号：KR1020110036667

申请日：2011-04-20

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  김호연 ,  박진실 ,  임미애 ,  오혜좌 ,  유준걸 ,  변재경

IPC: A61K31/428 ,  A61K38/17 ,  A61P19/02 ,  A61P17/00

CPC classification number: A61K38/1758 ,  Y10S514/885 ,  Y10S530/868

Abstract: PURPOSE: A composition for preventing or treating immunization diseases including P53 is provided to suppress inflammatory cytokine IL-17 which causes the immunization diseases. CONSTITUTION: A composition for preventing or treating immunization diseases includes P53 as an active ingredient. The P53 has the activity of preventing or treating the immunization diseases through the formation inhibition of the inflammatory cytokine. The inflammatory cytokine is IL-17. The composition additionally includes substances for promoting the express of the p53 or for promoting the activity of protein. The composition for preventing or treating includes polynucleotide which codes the P53. The polynucleotide ciphering the p53 protein is provided in a recombinant vector type which is connected to a vector which expresses the same. The expression vector which expresses the P53 protein is a non-virus vector or a viral vector.

Abstract translation: 目的：提供用于预防或治疗包括P53在内的免疫疾病的组合物，以抑制引起免疫疾病的炎性细胞因子IL-17。 构成：用于预防或治疗免疫疾病的组合物包括P53作为活性成分。 P53具有通过炎性细胞因子的形成抑制来预防或治疗免疫疾病的活性。 炎性细胞因子是IL-17。 该组合物还包括用于促进p53表达或促进蛋白质活性的物质。 用于预防或治疗的组合物包括编码P53的多核苷酸。 加密p53蛋白质的多核苷酸以连接到表达相同的载体的重组载体类型提供。 表达P53蛋白的表达载体是非病毒载体或病毒载体。

公开(公告)号：KR101182114B1

公开(公告)日：2012-09-12

申请号：KR1020100019671

申请日：2010-03-05

Applicant: 가톨릭대학교 산학협력단 ,  한림제약(주)

Inventor： 민준기 ,  조미라 ,  우윤주 ,  오혜좌 ,  정영옥 ,  이근혁 ,  최병선 ,  박진하 ,  곽은영

IPC: A61K31/4704 ,  A61K9/14 ,  A61K47/38 ,  A61P19/02

CPC classification number: A61K31/4704 ,  A61K9/2004

Abstract: 본 발명은 레바미피드 및 약학적으로 허용가능한 담체를 포함하는 골관절염의 예방 또는 치료용 약학 조성물을 제공한다. 상기 약학 조성물은 경구 투여용 형태일 수 있으며, 바람직하게는 정제 또는 캅셀제 형태의 고형 경구용 제형을 가질 수 있다. 또한, 상기 약학 조성물은 레바미피드가 0.5 내지 50 mg/kg, 더욱 바람직하게는 0.6 내지 6 mg/kg의 용량으로 경구투여되기에 적합한 단위 투여 형태(unit dosage form)로 제제화될 수 있다.

公开(公告)号：KR1020120095063A

公开(公告)日：2012-08-28

申请号：KR1020110014466

申请日：2011-02-18

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  박진실 ,  임미애 ,  이선영 ,  오혜좌 ,  류준걸

IPC: A61K38/16 ,  A61K38/20 ,  A61P37/00

CPC classification number: A61K38/1758 ,  A61K38/20 ,  C07K14/4713 ,  C07K14/4746

Abstract: PURPOSE: A composition for preventing or treating immunization diseases including p53 induced by il-27 is provided to increase expression of p53 by getting stimulation of the IL-27 and to enhance arthritis in animal models according to the expression of p53. CONSTITUTION: A composition for preventing or treating immunization diseases includes p53. The p53 has amino acid sequence described in the sequence number 1(SEQ ID NO:1) or 2. The composition additionally includes the interleukin-27(IL-27). The interleukin-27(IL-27) multiplies the activities of the gene expression of p53 or the p53 protein. The composition for preventing or treating immunization diseases includes a promoter and a vector containing polynucleotide which codes the p53. The polynucleotide has the base sequence described in the sequence number 3 or 4.

Abstract translation: 目的：提供一种用于预防或治疗由il-27诱导的免疫疾病包括p53的组合物，以通过刺激IL-27并根据p53的表达增强动物模型中的关节炎来增加p53的表达。 构成：用于预防或治疗免疫疾病的组合物包括p53。 p53具有序列号1（SEQ ID NO：1）或2所述的氨基酸序列。该组合物另外包括白细胞介素-27（IL-27）。 白介素-27（IL-27）将p53或p53蛋白的基因表达的活性相乘。 用于预防或治疗免疫疾病的组合物包括编码p53的启动子和含有多核苷酸的载体。 多核苷酸具有序列号3或4中描述的碱基序列。

公开(公告)号：KR1020120029342A

公开(公告)日：2012-03-26

申请号：KR1020110092596

申请日：2011-09-14

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  박미경 ,  오혜좌 ,  박민정 ,  전은주 ,  조석구

IPC: A61K31/225 ,  A61K31/21 ,  A61P35/00

Abstract: PURPOSE: A composition containing retinal for preventing or treating cancer or immune diseases is provided to enhance immune-modulating T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune disease contains retinal compounds of pharmaceutically acceptable salt thereof as an active ingredient. The retinal promotes or enhances regulatory T cell activity or proliferation. A method for reducing or suppressing differentiation of immature T cell into Th17 cell in vitro comprises a step of treating retinal compound or pharmaceutically acceptable salt to the undifferentiated T cells.

Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的视网膜的组合物，以增强免疫调节T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有其药学上可接受的盐的视黄醛化合物作为活性成分。 视网膜促进或增强调节性T细胞活性或增殖。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括将视黄醛化合物或药学上可接受的盐处理至未分化的T细胞的步骤。

公开(公告)号：KR101099021B1

公开(公告)日：2011-12-28

申请号：KR1020090035796

申请日：2009-04-24

Applicant: 가톨릭대학교 산학협력단 ,  에이치 엘 지노믹스(주)

Inventor： 민준기 ,  조미라 ,  박미경 ,  허유정 ,  박진실 ,  김호연 ,  오혜좌 ,  우윤주 ,  류종현 ,  김현규 ,  이근혁 ,  박진하 ,  곽은영 ,  전주연

IPC: A61K36/87 ,  A61P19/02

CPC classification number: A61K36/87

Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약학적으로 허용가능한 담체를 포함하는 골관절염(osteoarthritis)의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도의 씨 추출물, 골관절염

公开(公告)号：KR101096574B1

公开(公告)日：2011-12-20

申请号：KR1020080126216

申请日：2008-12-12

Applicant: 가톨릭대학교 산학협력단 ,  에이치 엘 지노믹스(주)

Inventor： 김호연 ,  민준기 ,  조미라 ,  박미경 ,  오혜좌 ,  허유정 ,  박진실 ,  우윤주 ,  류종현 ,  김현규 ,  이근혁 ,  박진하 ,  곽은영

IPC: A61K36/87 ,  A61P19/10

CPC classification number: A61K36/87

Abstract: 본 발명은 유럽종 포도(
Vitis vinifera )의 씨 추출물 및 약제학적으로 허용가능한 담체를 포함하는 골다공증의 예방 또는 치료용 약학 조성물을 제공한다.
유럽종 포도, 골다공증

公开(公告)号：KR1020110044490A

公开(公告)日：2011-04-29

申请号：KR1020090101194

申请日：2009-10-23

Applicant: 가톨릭대학교 산학협력단

Inventor： 조석구 ,  박민정 ,  박현실 ,  조미라

IPC: A61K35/28 ,  C12N15/10 ,  A61K48/00

CPC classification number: C07K14/495 ,  A61K35/28 ,  A61K38/00 ,  C12N5/0663 ,  C12N2501/15 ,  C12N2510/00 ,  A61K48/00 ,  C12N15/10 ,  A61K2300/00

Abstract: PURPOSE: A mesenchymsal stem cells and a composition containing the same for treating autoimmune diseases are provided to enhance autoantigen-specific CD4+ CD25+ Foxp3+ regulatory T cells and to treat autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains mesenchymal stem cells in which TFG-beta-encoding nucleotide sequence is introduced and pharmaceutically acceptable carrier. The TGF-beta-encoding nucleotide sequence is sequence number 2. The TGF-beta-encoding nucleotide sequence is introduced by adenovirus-associated vector. The mesenchymal stem cell is derived from bone marrow-derived mesenchymal stem cells or adipose-derived mesenchymal stem cells.

Abstract translation: 目的：提供间充质干细胞和含有其的用于治疗自身免疫性疾病的组合物，以增强自身抗原特异性CD4 + CD25 + Foxp3 +调节性T细胞并治疗自身免疫性疾病。 构成：用于治疗自身免疫性疾病的组合物含有引入TFG-β编码核苷酸序列的间充质干细胞和药学上可接受的载体。 TGF-β编码核苷酸序列是序列号2.由腺病毒相关载体引入TGF-β编码的核苷酸序列。 间充质干细胞衍生自骨髓间充质干细胞或脂肪来源的间充质干细胞。